<?xml version="1.0" encoding="UTF-8"?>

<wo-patent-document lang="fr" status="175" country="OA">
  <wo-bibliographic-data status="BR100 Migrated">
    <publication-reference>
      <document-id>
        <country>OA</country>
        <doc-number>1/2010/000300</doc-number>
        <kind>A</kind>
        <date>20131025</date>
      </document-id>
    </publication-reference>
    <classifications-ipcr>
      <classification-ipcr sequence="0001">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>A</section>
        <class>61</class>
        <subclass>K</subclass>
        <main-group>31</main-group>
        <subgroup>519</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0002">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>A</section>
        <class>61</class>
        <subclass>P</subclass>
        <main-group>35</main-group>
        <subgroup>00</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0003">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>D</subclass>
        <main-group>491</main-group>
        <subgroup>20</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
    </classifications-ipcr>
    <application-reference>
      <document-id>
        <country>OA</country>
        <doc-number>1/2010/000300</doc-number>
        <date>20090227</date>
      </document-id>
    </application-reference>
    <priority-claims>
      <priority-claim sequence="0001" kind="national">
        <country>US</country>
        <doc-number>61/067,843</doc-number>
        <date>20080229</date>
      </priority-claim>
      <priority-claim sequence="0002" kind="national">
        <country>US</country>
        <doc-number>61/116,809</doc-number>
        <date>20081121</date>
      </priority-claim>
    </priority-claims>
    <parties>
      <applicants>
        <applicant sequence="0001" app-type="applicant" designation="all">
          <addressbook lang="fr">
            <name>WYETH LLC</name>
            <address>
              <address-1>Five Giralda Farms, MADISON, New Jersey 07940</address-1>
              <country>US</country>
            </address>
          </addressbook>
          <nationality>
            <country/>
          </nationality>
          <residence>
            <country>US</country>
          </residence>
        </applicant>
      </applicants>
      <inventors>
        <inventor sequence="0001">
          <addressbook lang="fr">
            <name>BERGER, Dan Maarten</name>
            <address>
              <address-1>6 Irion Drive, NEW CITY, New York 10956</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0002">
          <addressbook lang="fr">
            <name>DI GRANDI, Martin Joseph</name>
            <address>
              <address-1>77 Phillipsburg Road, GOSHEN, New York 10924</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0003">
          <addressbook lang="fr">
            <name>DUNNICK, Alejandro Lee</name>
            <address>
              <address-1>27 North Franklin Avenue, Apt. 2A, NYACK, New York 10960</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0004">
          <addressbook lang="fr">
            <name>DUTIA, Minu Dhanjish</name>
            <address>
              <address-1>5 Amethyst Court, WEST NYACK, New York 10994</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0005">
          <addressbook lang="fr">
            <name>HOPPER, Darrin William</name>
            <address>
              <address-1>201 West 101st Street, Apt. 5A, NEW YORK, New York 10025</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0006">
          <addressbook lang="fr">
            <name>LEVIN, Jeremy Ian</name>
            <address>
              <address-1>19 Long Meadow Drive, NEW CITY, New York 10956</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0007">
          <addressbook lang="fr">
            <name>TORRES, Nancy</name>
            <address>
              <address-1>10 High Avenue, NYACK, New York 10960</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0008">
          <addressbook lang="fr">
            <name>WANG, Xiaolun</name>
            <address>
              <address-1>213 Fondiller Street, RIVER VALE, New Jersey 07675</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0009">
          <addressbook lang="fr">
            <name>ZHANG, Chunchun</name>
            <address>
              <address-1>551 Cleveland Avenue, RIVER VALE, New Jersey 07675</address-1>
              <country>US</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
      <agents>
        <agent sequence="0001" rep-type="agent">
          <addressbook lang="fr">
            <name>SCP NICO HALLE &amp; Co. LAW FIRM</name>
            <address>
              <address-1>ADRESSE A COMPLETER</address-1>
              <country>CM</country>
            </address>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <invention-title lang="fr">Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-A]pyrimidines, methods for preparation and uses thereof.</invention-title>
    <wo-term-of-grant>
      <date>20121231</date>
      <doc-number>015674</doc-number>
    </wo-term-of-grant>
    <wo-date-of-expiry>20290227</wo-date-of-expiry>
    <pct-or-regional-filing-data>
      <document-id>
        <country>US</country>
        <doc-number>PCT/US09/035422</doc-number>
        <date>20090227</date>
      </document-id>
    </pct-or-regional-filing-data>
    <pct-or-regional-publishing-data>
      <document-id>
        <country>IB</country>
        <doc-number>WO/09/108838</doc-number>
        <date>20090903</date>
      </document-id>
    </pct-or-regional-publishing-data>
    <wo-national-office-event national-office-event-type="Filed" doc-number="OA/1/2010/000300" event-name="Filing">
      <wo-national-office-event-date>
        <date>20090227</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-event national-office-event-type="175" event-name="-">
      <wo-national-office-event-date>
        <date>20100827</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-event national-office-event-type="Registered" doc-number="015674" event-name="Registration">
      <wo-national-office-event-date>
        <date>20121231</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-event national-office-event-type="Published" doc-number="BOPI N° 05/2012" event-name="Publication">
      <wo-national-office-event-date>
        <date>20131025</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-filing-data appl-type="BR Brevet" file-type="1">
      <kind-of-protection>BR Brevet PCT</kind-of-protection>
    </wo-national-office-filing-data>
  </wo-bibliographic-data>
  <abstract lang="fr">
    <p num="0001">Compounds of formula A : and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kineases.</p>
  </abstract>
</wo-patent-document>
